Pre-earnings options volume in Allogene Therapeutics (ALLO) is normal with puts leading calls 19:4. Implied volatility suggests the market is anticipating a move near 16.7%, or 18c, after results are released. Median move over the past eight quarters is 3.6%.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ALLO:
- Options Volatility and Implied Earnings Moves Today, August 13, 2025
- Is ALLO a Buy, Before Earnings?
- Strategic Adjustments and Technological Advancements Drive Buy Rating for Allogene Therapeutics
- Allogene Therapeutics: Strategic Adjustments and Positive Interim Data Justify Buy Rating
- Allogene Therapeutics downgraded to Neutral from Overweight at JPMorgan